DNA Repair Defects as Therapeutic Targets in Metastatic Prostate Cancer
Hematologist-oncologists, radiation oncologists, surgeons, other medical specialists, basic and translational research scientists, residents, fellows, and medical students need to be regularly updated on advances in the diagnosis and management of patients with hematologic disorders and related malignancies. The series aims to broaden the knowledge base of learners in these topic areas and improve their competencies to enhance the patient care experience and outcomes.
Physicians, medical students, fellows, and residents.
At the conclusion of the session, the participants should be able to:
Explain the biologic rationale of synthetic lethality in prostate cancer.
Distinguish the indications for PARP inhibitor monotherapy or combination therapy.
Review clinical trials in progress and future directions for use of PARP inhibitor as treatment for prostate cancer.
Identify the patient support needs for prevention of side effects from PARP inhibitor therapy.
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.75 AMA PRA Category 1 Credit™
- 0.75 Participation